Therapeutic Potential of Somatostatin and Its Analogues in Alzheimer's Disease: From Molecular Mechanisms to Preclinical Studies - PubMed
5 hours ago
- #Alzheimer's Disease
- #Somatostatin Analogues
- #Neurodegenerative Disorders
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options.
- Current treatments like acetylcholinesterase inhibitors and NMDA receptor antagonists offer only modest symptomatic relief without altering disease progression.
- The somatostatin (SST) system and its analogues (SSAs) show potential as multitarget therapies for AD.
- Somatostatin receptors (SSTR1-5) are involved in amyloid-β metabolism, tau phosphorylation, neuroinflammation, and synaptic plasticity.
- Preclinical studies indicate SSAs enhance amyloid clearance, reduce tau pathology, regulate APOE4 expression, and modulate microglial function.
- SSAs may provide broader therapeutic benefits if applied in early or prodromal stages of AD.
- Advances in delivery strategies, such as peptide modification and nanocarriers, improve the translational potential of SSAs.
- Challenges include poor blood-brain barrier permeability, incomplete mechanistic understanding, and limited clinical data.
- Integration of systems biology, precision medicine, and novel delivery technologies could enhance SSA-based interventions for AD.